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Abstract: In this studry 32 hyperglycemic
patients with type II DM were treated with
diet (7 patients), with gliclazide, an oral
antidiabetic agent (10 patients), or with
insulin (15 patients). The levels of
liporoteins, apolipoprotein A and B and LCAT
enzyme are measured before the therapy and
3 weeks after the achievement of glycemic
control. Treatment types are compared with
each other and with control group (10
normal persons) triglyseride (TG) and VLDL
levels which were found to be high in all of
the patients decreased in all groups to levels
similar to control group. TC (total
cholesterol), LDL, TC/HDL, LDL/HDL levels
found high before treatment in the OAD (oral
antidiabetic) group (p<0.05) were similar to
control values after treatment in the OAD
levels of all groups before the treatment
were similar to control group, but afterwards
it was significantly high in the OAD group.
Apo B level decreased after the therapy only
in the OAD group (p<0.05).

declined in both groups with the therapy and
were indifferent from control group in the
OAD group. LCAT levels didn’t change in any
of the conditions. Between treatment groups
there was no difference in lipoprotein, Apo A,
Apo B and LCAT levels before and after the
treatment. There was a positive correlation
between fasting blood glucose level (FBGL)
and TG and Apo B/Apo A, insulin level and
Apo B and Apo B/Apo A, TG and T.C, Apo B
and LDL/HDL, LDL and Apo B, HDL and Apo
A, but a negative correlation between the
activity and insulin level and macrovascular
complications of the disease, HDL and
proteinuria.

The higher levels of Apo B/Apo A in the OAD
and insulin group before the treatment
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Introduction
One of the dominant characteristics of diabetes
mellitus (DM) is the change in lipoprotein metabolism. In
cases with type II DM, the changes in lipoprotein
metabolism play a role in the development of
macrovascular complications and they are important
factors leading to an increase in mortality and morbidity.
In type II DM it has been reported that the peripheric
vascular disease in 5 fold higher and the mortality due to
atherosclerotic heart disease is 2-3 fold higher than the
normal population (1). Therefore, in the treatment of
DM, along the glycemic control the effects of treatment
type on lipoprotein metabolism play an important role in
the development of macrovascular complications.
Hence in our study in cases of type II DM with non

In conclusion, in patients with uncontrolled
type II DM lipid metabolism in altered and
with achievement of metabolic control these
alterations regress independent of treatment
type and the most beneficial alteration has
been observed in the OAD group.

regulated glycemic control we intended to study the
changes in lipoprotein metabolism and the effects of
glycemic control and treatment type on the changes in
lipoprotein metabolism after the glycemia has been
regulated.
Material and Method
The study population consisted of 32 DM patients,
partly new diagnosed and partly from the patients who
were followed up in the department of endocrinology and
a control group of ten healhy volunteers. In the selection
of the patients following criteria were taken into account:
1. Fasting blood glucose level (FBGL) 140 mg/dl,
postprandial glucose level (PGL) 200 mg/dl and above.
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2. HbAıc above 6%
3. The absence of any disease apart from DM which
can influence lipid levels.
4. The absense of any treatment which can influence
lipid levels.
5. The absense of ketoacidosis and chronic alcoholism.
6. The treatment type should be applied for the first
time.
The patients were starified into 3 groups according to
treatment:

Diet group: consisting of 7 patients, 4 men and 3
women, aged between 42-65 (mean 51.4±3.4) receiving
only diet therapy.
Oral antidiabetic group (OAD): consisting of 10
patients, 5 men and 5 women, aged between 41-66
(mean:55.2±2.8) and receiving in addition to diet 80320 mg/day gliclazide according to fasting blood glucose
level.
Insulin group: consisting of 15 patiens, 6 mean and
9 women, aged between 30-67 (mean:58±3) receiving in
addition to diet therapy conventional insulin therapy in a
dose of 35-90 U/day
All of the patients were hospitalized and in addition to
detailed history, physical examination and laboratory
investigations, examinations to find out DM complications
were made. The patients were charged out from the
hospital after the regulation of blood glucose
concentration and were called for an outpatient visit after
3 weeks. In this period they were warned not to change
their activities. At the next visit all of basic parameters are
controlled again.
Standart body weight of the cases are measured
according to Broca Index and they received 20-40 kcal/kg
diabetic diet according to their activities (15 % of total
calories consist of protein, 35 % of fat and 50 % of
carbohydrates). Body Mass Index (BMI) of the patients
before and after the treatment is calculated with the
formula:
BMI=Body weigt (kg)/Height2 (m2 )
The patients were stratified into 3 groups according
to their activities. The patients who can manage only their
own activities formed the 1st group, physically active
ones or the patients maintaining regular exercises
included in the 3rd group and the patients with an activity
between these two groups were in the second group. For
the detection of macrovascular complications the
presence of angina pectoris, claudicatio intermittens and
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past myocardial infarction has been investigated and
physical examination and ECG recording were done.
The patients without macrovascular complications,
with ischemic heart disease and with previous mycocardial
infarction attached were classified in to grups 0,1,2
respectively.
Before the treatment and 3 week after the control of
glycemia blood specimens were taken after a 12 hour fast
and fasting blood glucose level, one-hour postprandial
glucose, insulin, HbA1c, total cholesterol (TC), HDLcholesterol and trigliserid (TG) levels were measured. An
aliquot of serum was taken from blood specimens and
refrigerated at -35˚C in a deep freeze for investigations of
Apo A, Apo B and lecithin cholesterol acyltranferase
(LCAT) enzyme. HbA1c is measured with microcolon
chromatography method (N:3 -6 %). Fasting insulin
levels (FIL) were measured by radioimmunoassay (RIA)
(N:0-30 uIU/ml). Protein was measured in 24 hour urine
sample with the modified Purdy method quantitatively
and creatinine was determined by alkaline picrat method.
Fasting blood glucose level (N:70-110 mg/dl), TC
(N:112-253 mg/dl), TG (N:25-170 mg/dl) levels were
determined with a Dacos autoanalyser.
LDL and VLDL levels were calculated by Friedwald
formula. Apo A and Apo B levels were measured
immunoturbometrically. LCAT enzyme was determined by
the calorimetric method of Nagasaki T and Akanuma Y.
except two patients in insulin group (2).
For the statistical evaluation of the data, t-test, x2
test, Pearson and Spearman’s correlation analysis were
used.
Results
The characteristics of control group and treatment
groups are given in Table 1. Laboratory findings and
statistical comparisons of all groups and of control group
are summarized in Table 2 and 3.
1. The fasting blood glucose levels decreased in diet
group (p<0.01), in insulin and OAD group (p<0.001)
statistically significantly after therapy.
2. In our cases prominent hyperinsulinemia has not
been detected. Only in the OAD group a significant
increase in comparison to control group before the
therapy is detected (p<0.05), but after the therapy it
became similar to levels in control group.
3. In all of the treatment groups the most prominent
change was observed in the levels of TG and VLDL before
the treatment. TG and VLDL levels which were

E. VARDARELİ, B. EFE, F. AKYÜZ, M. İNAL, E. ERENOĞLU

Table 1.

The characterictics of control group and treatment group
CONTROL GROUP n=10

DIET GROUP n=7

OAD GROUP n=10

INSULIN GROUP n=15

AGE (yrs)

53.100 ± 2.69

51.429 ± 1.85

55.200 ± 2.79

58.067 ± 3.07

WEIGHT (kg)

69.600 ± 2.15

88.857 ± 5.18

74.650 ± 3.71

66.467 ± 3.00

BMI (kg/m2)

27.609 ± 0.45

32.964 ± 1.55

29.058 ± 1.08

26.041 ± 1.55

HbAlc (%)

3.920 ± 0.39

7.911 ± 0.75

10.334 ± 1.12

10.467 ± 0.77

1.543 ± 1.00

4.250 ± 1.66

9.433 ± 2.31

PBGL (mg/dl)

80.400 ± 1.42

172.571 ± 14.12

274.800 ± 24.45

331.000 ± 29.57

INSULIN (uIU/ml)

22.200 ± 1.00

22.857 ± 2.81

29.800 ± 2.43

28.133 ± 5.36

1

2 (20 %)

2 (28.6 %)

4 (40 %)

9 (69 %)

2

7 (70 %)

4 (57.1 %)

6 (60 %)

4 (26.7 %)

3

DURATION OF DM (yrs)

ACTIVITY

1 (10 %)

1 (14.3 %)

-

2 (13.3 %)

MACROVASCULER 0

-

6 (85.7 %)

7 (70 %)

8 (53.3 %)

COMPLICATIONS

1

-

1 (14.2 %)

3 (30 %)

5 (33.3 %)

2

-

-

-

2 (13.3 %)

Table 2.

Before (BT) and after treatment (AT), all of the therapy groups statistical findings.
OAD BT-AT

Hba1c (%)

BT OAD-CONTROL AT OAD-CONTROL

INSULIN BT-AT BT INSULIN-CONTROL AT INSULIN-CONTROL

**

AGE (yrs)

DIET BT-AT

***

ns

BT DIET-CONTROL AT DIET-CONTROL

*

ns

ns

WEIGHT (kg)

*

ns

ns

ns

ns

ns

*

**

**

BMI (kg/m2)

*

ns

ns

ns

ns

ns

**

**

**

FIL (uIU/ml)

ns

*

ns

*

ns

ns

ns

ns

ns

FBGL (mg/dl)

***

***

***

***

***

**

***

***

***

TG ‘mg/dl)

ns

*

ns

***

*

ns

**

*

ns

T.C (mg/dl)

ns

**

*

ns

ns

ns

ns

ns

ns

HDL (mg/dl)

*

ns

*

ns

ns

ns

ns

ns

ns

VLDL (mg/dl)

ns

*

ns

***

*

ns

**

*

ns

LDL (mg/dl)

ns

*

ns

ns

ns

ns

ns

ns

ns

T.C / HDL

ns

*

ns

ns

ns

ns

ns

ns

ns

ldl / HDL

ns

*

ns

ns

ns

ns

ns

ns

ns

APO A (mg/dl)

ns

ns

ns

ns

ns

ns

ns

ns

ns

APO B (mg/dl)

*

*

ns

ns

ns

ns

ns

ns

ns

APO B / APO A

*

**

ns

ns

**

*

ns

ns

ns

LCAT (nmol/ml/hrs)

ns

ns

ns

ns

ns

ns

ns

ns

ns

*p<0.05 **p<0.01 ***p<0.001

significantly higher than control group (p<0.05)
decreased to levels similar in the control group after the
correction of the glycemia, this decline was most
prominent in insulin group (p<0.001).
4. Before the treatment T.C, LDL, LDL/HDL, TC/HDL
levels were higher than the control group only in the OAD

group (p<0.05), but after the treatment all of them
decreased. LDL, LDL/HDL, TC/HDL levels were indifferent
from control group.
5. HDL level wasn’t low in any of the groups and only
in OAD group it did increase after the treatment
(p<0.05).
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Table 3.

Before (BT) and after treatment (AT), all of the therapy groups and control group’s labotarory findings.
BT DIET GROUP n=7

AT DIET GROUP n=7

BT OAD GROUP n=10

AT OAD GROUP n=10

BT INSULIN GROUP n=15

AT INSULIN GROUP n=15

CONTROL GROUP

HbA1c (%)

7.911±0.75

10.334±1.12

10.467±0.77

3.920±0.39

AGE (yrs)

51.429±3.44

55.200±2.79

58.067±3.07

53.100±2.69

WEIGHT (kg)

88.857±5.18

87.000±4.81

74.650±3.71

73.750±3.57

66.467±3.00

66.300±2.83

69.600±2.15

BMI (kg/m2)

32.464±1.54

32.303±1.52

29.058±1.08

28.700±1.03

26.040±1.55

25.959±1.46

27.609±0.45

FIL (uIU/ml)

22.857±2.81

22.857±2.34

29.800±2.43

23.200±2.32

28.133±5.36

37.467±6.02

22.200±1.10

FBGL (mg/dl)

172.571±14.12

115.571±9.35

247.800±24.45

113.200±6.71

331.000±29.57

117.267±5.31

80.400±1.42

PGL (mg/dl)

267.429±31.37

181.286±10.69

323.500±29.85

168.000±8.22

412.000±34.39

162.000±7.07

TG (mg/dl)

181.714±27.37

141.143±20.75

180.100±20.01

150.700±10.18

193.000±21.93

146.600±16.88

112.600±16.77

TC (mg/dl)

219.429±13.83

216.000±13.53

240.800±14.30

231.100±12.88

227.267±19.38

221.533±15.26

183.600±13.13

HDL (mg/dl)

49.286±4.48

44.429±3.03

45.200±3.35

52.500±3.07

41.400±3.31

46.133±4.18

44.100±1.81

VLDL (mg/dl)

36.343±5.47

28.229±4.15

37.000±4.85

30.140±2.03

38.600±4.49

29.720±3.38

22.520±3.35

LDL (mg/dl)

133.800±12.63

143.314±12.20

158.600±10.99

148.460±11.82

144.520±15.99

142.827±13.38

116.980±11.63

T.C/HDL

4.597±0.44

4.971±0.41

5.514±0.44

4.470±0.40

5.662±0.56

5.058±0.54

4.243±0.35

LDL/HDL

2.839±0.36

3.296±0.35

3.662±0.33

2.971±0.37

3.634±0.46

3.345±0.46

2.712±0.28

Apo A (mg/dl)

115.329±8.19

110.443±7.04

115.750±4.27

107.480±4.89

101.040±8.85

96.440±6.99

107.950±7.17

Apo B (mg/dl)

132.571±7.31

130.286±10.89

154.500±12.33

130.500±11.61

122.420±11.37

118.860±9.96

108.160±12.95

Apo B/Apo A

1.176±0,09

1.183±0.05

1.345±0.09

1.204±0.08

1.445±0.12

1.262±0.09

0.981±0.07

44.970±17.00

44.10±8.14

37.719±3.63

43.513±1.72

43.189±6.53

48.902±6.10

39.579±6.50

LCAT (nmol/ml/hrs)

6. Apo A level didn’t show a significant change in any
of the groups whereas Apo B level was detected
significantly high in OAD group before the treatment
(p<0.05), but after the treatment in became similar to
levels in control group.
7. Apo B/Apo A level was found higher than control
group in OAD and insulin groups before the treatment
(p<0.01), after the treatment a decrease was observed in
both groups, with a more prominent pattern in the OAD
group.
8. The achievement of glycemic control with gliclazide
and insulin therapy resulted in a statistically insignificant
increase in the activity of LCAT.
9. The comparison of treatment groups with each
other revealed no statistical change in lipoprotein levels
before and after the therapy.
10. Thereas a positive correlation between fasting
insulin level and Apo A and Apo A/Apo B (p<0.05) and a
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negative correlation between fasting insulin level and
activity (p<0.001).
11. A positive correlation is detected between
fasting blood glucose level and TG and Apo A/Apo B.
12. Thereas a positive correlation between TC value
and TC, TC/HDL, LDL/HDL and Apo B value (p<0.01) an
a negative correlation between TG and activity
(p<0.001).
13. Between LDL and VLDL levels and Apo B, a
positive correlation is detected (p<0.001), HDL level is in
positive correlation with Apo A (p<0.01) and in negative
correlation with proteinuria (p<0.05).
14. Macrovascular disease symptoms are negatively
correlated with activity (p<0.01).
15. A correlation between blood lipids and the
duration of diabetes, HbA1c retinopathy and neuropathy
symptoms could not be defined.
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Discussion
In the decision of therapy plan for diabetic patients
the effect of therapy on chronic complications should be
considered. In diabetes mellitus blood lipid levels are
under the influence of factors like age, physical activity,
body weight, BMI, the duration of diabetes, the level of
glycemic control, complications specific for diabetes and
facting insulin level (1, 3, 4).
In our study, age and level of physical activity was
similar in all of the treatment groups and in comparison
of each group with control group.
In diet group where the body weight was the highest,
we detected a positive correlation between body weight
and TG and VLDL and in insulin group between BMI and
fasting insulin level. This correlation is compatible with
previous studies (5, 6).
Our findings support studies reporting that lipid levels
are independent of the duration of the diabetes (7, 8).
Age in as in comparable studies in our study a positive
correlation between fasting blood glucose level and TG,
VLDL, Apo A was detected, but an association with HDL
wasn’t found (8-12).
Thereas a negative correlation between HDL level and
only proteinuria among the diabetic complications. In the
literature this correlation is explained by the urinary loss
of HDL and ApoA (13). Our finding suggests that
macrovascular complication risk is increased in patients
with proteinuria.
Fasting insulin level in accepted as a sensitive criterion
for the development of atherosclerosis (14). In our study
we detected a significant association between insulin level
and ApoB and ApoB/ApoA values as also being remarkable
indicators of the development of atherosclerosis.
In our study before therapy, insulin level is high only
in OAD group in comparison to control group, but
declined after therapy to levels indiferent from control
group. It has been reported that sulphonylurea drugs
increase the number of insulin receptors and the
sensitivity of the tissue to insulin, that they do not cause
hyperinsulinaemia during therapy restoring phase 1
insulin release which is defective in type II DM and by this
way the patients are protected from the anabolic effect of
the insulin (15).
In accordance with these studies, in our patients in
OAD group body weight has declined significantly after
therapy.
The most frequent finding in lipid metabolism in type
II DM is the increase in TG and VLDL levels (1, 3). We

found TG and VLDL levels high in all of the treatment
groups before glycemic control. In our study too, as in
similar studies, in patients receiving diet (16),
sulphonylurea (17) and insulin most prominently (18),
TG and VLDL levels declined after achievement of
glycemic control. The relation of macrovascular
complications and TG found elevated in DM is still
controversial. In some studies the correlation of TG and
atherosclerosis has been shown (19). Some authors say
that the low HDL level cause this association (19, 20). But
in other studies it was proposed that the increase of TG
and cholesterol content of VLDL result in a destruction of
its structurend that this abnormal VLDL forms a risk of
atherosclerosis independent of HDL level by stimulating
cholesterol ester synthesis in macrophages, precursors of
foamy cells (9, 21). As in the study of Noyah Al Muhtaseb
et al, we found a positive correlation between TG level
and T.C., T.C/HDL, LDL/HDL and Apo B, being important
indicators of atherosclerosis risk in our study (12).
HDL level, an important criterion because of its
inverse relation with atherosclerosis is found low
especially in diabetic patients with high TG (5, 7, 18). But
in our study, in spite of hypertrigliseridemia before
therapy we found that HDL level was similar to control
group which was quite revelant from the point of factors
influencing HDL.
There wasn’t a significant change in HDL level in diet
and insulin group but in OAD group HDL level increased
significantly in comparison to control group. In previous
studies the effects of sulphonylurea drugs on HDL level
gave conflicting results and became a matter of debate.
The comparison of patients receiving diet, sulphonylurea
and insulin therapy shows in some studies that HDL level
is low only in patients receiving sulphonylurea or that
with sulphonylurea therapy there isn’t any beneficial
effect on HDL level (11, 22). Whereas in some other
studies it has been detected an increase on HDL level with
sulphonylurea therapy (17, 23). In DM patients low HDL
level is explained by the decreased production due to the
slowing of TG and VLDL catabolism and by the increased
catabolism due to increased activity of hepatic lipase (HL)
(24).
It is proposed that a decrease in the activity of the
enzyme LCAT which plays an important role in HDL
metabolism can have a negative influence on HDL level
(24). Moreover in diabetic patients is reported that the
increase in the free cholesterol content of LDL and VLDL
is associated with a decline in esterification rate (25).
Therefore LCAT enzyme activity becomes important more
and more. But in still a small number of studies done on
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diabetic patients LCAT levels are found variably. In a study
carried out on 80 diabetic patients HDL levels are found
lower than control group, LCAT acivity similar to control
group (12). In another study in patients receiving insulin
therapy thereas no change in HDL levels after therapy but
a decline in LCAT activity, this fact couldn’t be explained
(22). In our study in all treatment groups LCAT levels
were similar to control group before and after therapy.
ApoB, ApoB / ApoA and T.C/HDL, LDL/HDL levels which
are important indicators of atherosclerosis were high in
OAD group before therapy and the decline of these
factors after therapy shows that the disturbed inverse cholesterol transport is restored again. Our study in
compatible with studies reporting a decline in ApoB and
ApoB/ApoA levels with sulphonylurea therapy (12, 22).
As in similar studies ApoB/ApoA level found high in insulin
group declined with therapy and this shows that insulin

therapy influences the risk of atherosclerosis positively
(11, 12). In our study VLDL, TG, TC, LDL, HDL, ApoA,
ApoB, ApoB/ApoA and LCAT levels didn’t have a
statistically significant change before and after therapy
between treatment groups.
In insulin group although there was a significant
increase in insulin level after therapy, it couldn’t be found
a statistical difference between groups. This finding
suggests that the level of hyperinsulinaemia is not high
enough to increase the risk of atherosclerosis. All of these
findings indicate that in type II DM all of the negative
changes in lipid metabolism are corrected or regress with
the achievement of metabolic control and the regulation
of diet in all treatment groups. Unlike some authors, we
conluded that the most beneficial effect on HDL
metabolism is seen on the patients receiving
sulphonylurea therapy.
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